LASIX (furosemide) by Bausch Health is clinical pharmacology investigations into the mode of action of lasix have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. First approved in 1966.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
LASIX (furosemide) is a loop diuretic approved in 1966 that inhibits sodium and chloride reabsorption in the proximal tubule, distal tubule, and loop of Henle. It is indicated for edema and fluid overload associated with congestive heart failure, renal disease, and hepatic cirrhosis. The drug has a rapid onset (within 1 hour) and peak effect within 1–2 hours, with a 6–8 hour duration of action.
Product is in mature lifecycle stage approaching loss of exclusivity with modest Part D volume (7.4K claims in 2023), indicating a consolidating team focused on retention and generic preparation.
CLINICAL PHARMACOLOGY Investigations into the mode of action of LASIX have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that LASIX inhibits primarily the absorption of sodium and…
Worked on LASIX at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Loop Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on LASIX offers limited growth upside given its mature, commoditized status and approaching loss of exclusivity; roles are primarily focused on defending market share, managing costs, and ensuring supply reliability. Career development is better suited for professionals seeking experience in legacy brand management and generic transition strategy rather than innovation or high-growth opportunities.